Adoport: new tacrolimus brand

Unsupervised switching between different formulations of tacrolimus can lead to graft rejection
Unsupervised switching between different formulations of tacrolimus can lead to graft rejection

Adoport is a new brand of tacrolimus available from Sandoz. The 500 microgram, 1mg and 5mg capsules are indicated for the prevention and treatment of transplant rejection.

As with ciclosporin, the MHRA advises that different brands of tacrolimus are not interchangeable without careful therapeutic monitoring.

View Adoport drug record

Further information: Sandoz

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Skin cancer warning for actinic keratosis treatment

Skin cancer warning for actinic keratosis treatment

Patients treated with ingenol mebutate (Picato) should...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Drug shortages - live tracker

Drug shortages - live tracker

Added: Accupro, Dermovate, Norinyl-1.
Use our...

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.